Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31044611 | 0.83 | MAPK1 (0.57) | MAPK1GRM5CHRM2SIGMAR1EGLN1 | |
| SCHEMBL16011728 | 0.83 | MAPK1 (0.57) | MAPK1GRM5CHRM2SIGMAR1EGLN1 | |
| SCHEMBL4495255 | 0.83 | EGLN1 (0.46) | MAPK1GRM5CHRM2SIGMAR1EGLN1 | |
| SCHEMBL155925 | 0.80 | MAPK1 (0.54) | MAPK1GRM5CHRM2SIGMAR1KDM4E | |
| SCHEMBL31044569 | 0.80 | MAPK1 (0.54) | MAPK1GRM5CHRM2SIGMAR1KDM4E | |
| SCHEMBL15494738 | 0.79 | MAPK1 (0.53) | MAPK1GRM5CHRM2SIGMAR1KDM4E | |
| SCHEMBL22134763 | 0.79 | MAPK1 (0.53) | MAPK1GRM5CHRM2SIGMAR1KDM4E | |
| SCHEMBL15494739 | 0.78 | MAPK1 (0.51) | MAPK1GRM5CHRM2SIGMAR1KDM4E | |
| SCHEMBL2109394 | 0.78 | MAPK1 (0.51) | MAPK1GRM5CHRM2SIGMAR1EGLN1 | |
| SCHEMBL159424 | 0.78 | MAPK1 (0.59) | MAPK1GRM5CHRM2SIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
| EP-1853269-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006093832-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | MAPK1 1367/4885GRM5 278/4885CHRM2 914/4885 |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | MAPK1 1367/4885GRM5 278/4885CHRM2 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.